CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Potassium Iodidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00946296
NCT00946296Phase 4Completed
CompareCT.gov

Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease

University of Massachusetts, Worcester·interventional·Posted Jul 24, 2009·Updated Dec 15, 2015

In Brief

A Phase 4 clinical trial evaluating Potassium Iodide for Graves Disease and Hyperthyroidism. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves Disease, Hyperthyroidism
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 24, 2009
Enrollment StartApr 1, 2005
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 16.9 years ago

Interventions

Potassium Iodidedrug

8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.